NewAmsterdam Pharma (NAMS) news
Recent news
NewAmsterdam Pharma reports inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Aug 6, 2026NewAmsterdam Pharma Company N.V. - topline data from Rubens Phase 3 expected by year-end 2026
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announced that RUBENS Phase 3 trial data is expected by year-end 2026. The RUBENS trial is evaluating obicetrapib, either alone or in combination with ezetimibe, in type 2 diabetes or metabolic syndrome patients who require additional LDL-C lowering…
AInvest Wire · Aug 5, 2026NewAmsterdam Pharma Company N.V. - Prevail interim analysis planned for Q4 2026, result expected Q1 2027
AInvest Wire · Aug 5, 2026NewAmsterdam Pharma Company N.V. - announces positive CHMP opinion for obicetrapib and obicetrapib/ezetimibe
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) and its partner Menarini Group have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorization for Ubeslo® (obicetrapib 10 mg…
AInvest Wire · Aug 5, 2026NewAmsterdam Pharma shares rise on positive Alzheimer's cholesterol treatment data
NewAmsterdam Pharma shares rise on positive Alzheimer's cholesterol treatment data NewAmsterdam Pharma (NAMS) saw its shares rise following the announcement of positive topline data from the Phase 3 BROADWAY clinical trial. The trial, which focused on lowering low-density lipoprotein cholesterol…
AInvest Wire · Jun 9, 2025Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.